Analyst Price Targets — BNTC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 12, 2026 12:14 pm | — | Evercore ISI | $25.00 | $12.01 | TheFly | Benitec Biopharma initiated with an Outperform at Evercore ISI |
| November 24, 2025 11:16 am | Raghuram Selvaraju | H.C. Wainwright | $32.00 | $13.26 | TheFly | Benitec Biopharma price target lowered to $32 from $35 at H.C. Wainwright |
| November 4, 2025 5:30 pm | — | H.C. Wainwright | $35.00 | $15.69 | TheFly | Benitec Biopharma price target raised to $35 from $28 at H.C. Wainwright |
| November 4, 2025 10:42 am | — | JMP Securities | $22.00 | $15.86 | TheFly | Benitec Biopharma price target raised to $22 from $20 at Citizens JMP |
| September 16, 2025 12:08 pm | Andreas Argyrides | Oppenheimer | $29.00 | $13.66 | TheFly | Benitec Biopharma price target lowered to $29 from $35 at Oppenheimer |
| October 14, 2024 8:24 am | Silvan Tuerkcan | JMP Securities | $18.00 | $10.86 | TheFly | Benitec Biopharma price target raised to $18 from $16 at JMP Securities |
| October 14, 2024 6:36 am | Silvan Tuerkcan | JMP Securities | $16.00 | $10.86 | TheFly | Benitec Biopharma price target lowered to $16 from $18 at JMP Securities |
| October 14, 2024 6:05 am | Mani Foroohar | Leerink Partners | $13.00 | $10.86 | StreetInsider | Leerink Partners Reiterates Outperform Rating on Benitec BioPharma (BNTC) |
| September 24, 2024 7:53 am | Yasmeen Rahimi | Piper Sandler | $30.00 | $8.88 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Benitec BioPharma (BNTC) |
Latest News for BNTC
Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatment and further improvements in depth of response following treatment with high dose BB-301 at the 3-month post-treatment follow-up time-point, with both doses demonstrating disease modifying…
- Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 completers, 24-month post-treatment follow-up results for the first Cohort 1 Patient, and interim clinical results for the first Cohort 2 Patient - BB-301 is the only clinical-stage therapeutic agent in development for the treatment of dysphagia in patients diagnosed with OPMD…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BNTC.
U.S. House Trading
No House trades found for BNTC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.